Overview

A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The aim of this phase 1b study in Chinese patients with ER+/Her2- advanced breast cancer is to evaluate the safety and tolerability of ZN-c5 at dose of 50 mg and 150 mg QD well tolerance established in the previous oversea study in non-Chinese patients.
Phase:
Phase 1
Details
Lead Sponsor:
Zentera Therapeutics HK Limited